| Mrs Jennifer Lee Iannucci, PT | |
|
2889 Fairfield Avenue, Bridegport, CT 06606-1744 | |
| (203) 913-6978 | |
| Not Available |
| Full Name | Mrs Jennifer Lee Iannucci |
|---|---|
| Gender | Female |
| Speciality | Physical Therapy |
| Experience | 29 Years |
| Location | 2889 Fairfield Avenue, Bridegport, Connecticut |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1831128834 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 2251X0800X | Physical Therapist - Orthopedic | 005735 (Connecticut) | Primary |
| Provider Name | Eclectic Physical Therapy Llc |
|---|---|
| Provider Type | Part B Supplier - Physical/occupational Therapy Group In Private Practice |
| Provider Identifiers | NPI Number: 1730421397 PECOS PAC ID: 5991029126 Enrollment ID: O20150119000088 |
News Archive
New research published in the International Journal of Pharmaceutics demonstrates that 'good' bacteria in the live probiotic SymproveTM can successfully reach and colonize the gut, where they go on to change the existing gut flora. They are also capable of modifying immune response.
Together with his team, Prof. Christoph Ploner, director of the Department of Neurology at the Virchow campus, examined a professional cellist who suffered from encephalitis caused by a herpes virus. As a result of the inflammation, the patient developed serious disturbances in memory. Both his memory for the past (retrograde amnesia), as well as the acquisition of new information (anterograde amnesia) were affected.
Nektar Therapeutics today announced positive preliminary initial results from a two-stage Phase 2 clinical study evaluating single-agent NKTR-102 in women with advanced/metastatic breast cancer patients who have received a prior taxane. The increased use of taxanes in breast cancer often renders tumors resistant to these drugs by the time the disease recurs, thereby underscoring the urgent need for new treatment options with novel mechanisms of action for metastatic disease.
Invincibles, the "strong and healthy young adults who have no experience with wallet-crippling illness and feel they have no need for coverage," may be "the most likely to be affected by the reform effort" outlined by President Barack Obama on Wednesday, The Baltimore Sun reports. "Adults ages 18 to 34 comprise more than half of the nation's uninsured.
Ipsen, an innovation-driven global specialty pharmaceutical group and Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, announce the launch by Ipsen in France of Decapeptyl(R) LP 22.5 mg 6-month sustained-release formulation for the treatment of locally advanced or metastatic hormone-dependent prostate cancer.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Mrs Jennifer Lee Iannucci, PT 46 Driftwood Ln, Trumbull, CT 06611-1861 Ph: (203) 880-5221 | Mrs Jennifer Lee Iannucci, PT 2889 Fairfield Avenue, Bridegport, CT 06606-1744 Ph: (203) 913-6978 |
News Archive
New research published in the International Journal of Pharmaceutics demonstrates that 'good' bacteria in the live probiotic SymproveTM can successfully reach and colonize the gut, where they go on to change the existing gut flora. They are also capable of modifying immune response.
Together with his team, Prof. Christoph Ploner, director of the Department of Neurology at the Virchow campus, examined a professional cellist who suffered from encephalitis caused by a herpes virus. As a result of the inflammation, the patient developed serious disturbances in memory. Both his memory for the past (retrograde amnesia), as well as the acquisition of new information (anterograde amnesia) were affected.
Nektar Therapeutics today announced positive preliminary initial results from a two-stage Phase 2 clinical study evaluating single-agent NKTR-102 in women with advanced/metastatic breast cancer patients who have received a prior taxane. The increased use of taxanes in breast cancer often renders tumors resistant to these drugs by the time the disease recurs, thereby underscoring the urgent need for new treatment options with novel mechanisms of action for metastatic disease.
Invincibles, the "strong and healthy young adults who have no experience with wallet-crippling illness and feel they have no need for coverage," may be "the most likely to be affected by the reform effort" outlined by President Barack Obama on Wednesday, The Baltimore Sun reports. "Adults ages 18 to 34 comprise more than half of the nation's uninsured.
Ipsen, an innovation-driven global specialty pharmaceutical group and Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of prescription drugs that target unmet medical needs, announce the launch by Ipsen in France of Decapeptyl(R) LP 22.5 mg 6-month sustained-release formulation for the treatment of locally advanced or metastatic hormone-dependent prostate cancer.
› Verified 6 days ago